Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.

Julie Ryan WolfAnita ChenJill WieserBrad JohnsonLauren BaughmanGayin LeeEleanor PopeAbigail FrancoTanzy LoveLisa A Beck

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2024)

Our results demonstrated that topical treatment for 12 weeks was more beneficial than 6 weeks, with TAC improving more PROs than CRIS. Future trials should implement PROs to fully understand the impact of AD treatments.

Keyphrases

atopic dermatitis
gestational age
case report
current status
type diabetes
metabolic syndrome
wound healing
glycemic control